Clinical Trial Update: Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons [Phase 1]

View source ↗

Summary

Six-month Phase 1 study evaluating gentamicin as a stop-codon read-through therapy for Duchenne Muscular Dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Gentamicin (gentamicin)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Duchenne Muscular Dystrophy | Phase 1 | Status: COMPLETED